Attached files
| file | filename |
|---|---|
| EX-4.5 - EX-4.5 - Aptevo Therapeutics Inc. | apvo-ex45_509.htm |
| EX-21.1 - EX-21.1 - Aptevo Therapeutics Inc. | apvo-ex211_10.htm |
| EX-23.2 - EX-23.2 - Aptevo Therapeutics Inc. | apvo-ex232_11.htm |
| EX-32.1 - EX-32.1 - Aptevo Therapeutics Inc. | apvo-ex321_12.htm |
| EX-31.1 - EX-31.1 - Aptevo Therapeutics Inc. | apvo-ex311_7.htm |
| EX-31.2 - EX-31.2 - Aptevo Therapeutics Inc. | apvo-ex312_8.htm |
| EX-32.2 - EX-32.2 - Aptevo Therapeutics Inc. | apvo-ex322_6.htm |
| 10-K - 10-K - Aptevo Therapeutics Inc. | apvo-10k_20201231.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements of Aptevo Therapeutics Inc. of our report dated March 31, 2021, relating to the 2020 consolidated financial statements of Aptevo Therapeutics Inc., appearing in this Annual Report on Form 10-K for the year ended December 31, 2020.
|
|
• |
Registration Statement in Form S-8 (No. 333-213108) pertaining to the Converted Equity Awards Incentive Plan and 2016 Stock Incentive Plan of Aptevo Therapeutics Inc., |
|
|
• |
Registration Statement on Form S-8 (No. 333-219875) pertaining to the 2016 Stock Incentive Plan of Aptevo Therapeutics Inc., |
|
|
• |
Registration Statement on Form S-8 (No. 333-226717) pertaining to the 2018 Stock Incentive Plan of Aptevo Therapeutics Inc., |
|
|
• |
Registration Statement on Form S-3 (No. 333-221499 and No. 333-251318) of Aptevo Therapeutics Inc., and |
|
|
• |
Registration Statement on Form S-3 (No. 333-229115) of Aptevo Therapeutics Inc. |
/s/ Moss Adams LLP
Seattle, Washington
March 31, 2021